Implementation of pharmacogenomics and artificial intelligence tools for chronic disease management in primary care setting

HIGHLIGHTS

• who: Patrick Silva and collaborators from the The most obvious challenge with clinical roll-out of the IPGx model is that most of the bioanalytic methodologies described herein are not currently reimbursed by payers and disappointingly, out of reach for most primary care practicesThe triggers for genotyping the patients in our test case were rather compelling cases with symptomatology that could with relative ease be attributed to pharmacological root causes: CYP , overload, ACB, and drug-drug and drug-gene interactions. However, this practice is not currently a reimbursable use case for ordering pharmacogenomic testing or clinical pharmacokinetic . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.